Piramal Pharma Solutions expands peptide API facility with advanced spray drying suite

August 05, 2026 | Wednesday | News

A new spray drying suite with Band 5 containment capacity at dedicated peptide facility in Turbhe

Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma, has launched a state-of-the-art spray drying suite at its dedicated peptide development and manufacturing facility in Turbhe.

This strategic expansion enables PPS to address the complex formulation challenges associated with peptides and other complex molecules and support the growing demand for these innovative molecules.

Spray drying transforms liquid formulations into dry powders in a single step, enabling drug developers to enhance bioavailability, achieve precise particle size, and process sensitive compounds safely. This technique is especially critical for peptides, which are unstable at high temperatures and often require strict control over particle properties. Its gentle and efficient nature enables drug developers to improve solubility, streamline scale-up, and increase speed, all while preserving the molecular integrity of their peptide API.

The new spray drying suite operates as a closed-loop system, equipped with its own inert gas supply and advanced safety measures, including specialized HVAC, airlocked entries and exits, operator isolation, and a dedicated cleaning area. This enables the safe handling of potent compounds and organic solvents requiring up to Band 5 containment. To further strengthen these capabilities, the processing area maintains ISO Class 8 (Class 100,000) cleanliness standards, ensuring strict control of the environment throughout operations.

Engineered for small-volume, high potency batches, the unit supports a feed rate of up to 1 liter per hour. It can spray dry highly concentrated solutions — even those with up to 30% water content — making it particularly valuable for the formulation of biomolecules and large peptides. Under optimal conditions, the suite can also be leveraged for low-volume small-molecule formulations.

Comments

× Your session has expired. Please click here to Sign-in or Sign-up

Have an Account?

OR

Forgot your password?

OR

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy